Literature DB >> 18348469

The effect of four different types of diet on the bioavailability of loracarbef.

A T Bapujee1, T Singh, T Ahmed, T Monif, N Saha, P L Sharma.   

Abstract

This randomized open-label single-dose crossover pharmacokinetic study was carried out to assess the effect of different diets on the bioavailability of loracarbef in 24 healthy male volunteers. A single dose of loracarbef in 200-mg tablet form was administered at 5 different times: after overnight fasting, after two vegetarian (high-fat and low-fat) diets, and following two non-vegetarian (high-fat and low-fat) diets. Serial blood samples were collected up to 10 h post-dose. Serum loracarbef concentrations were determined by a validated high performance liquid chromatographic (HPLC) method. Area under curve (AUC) values were significantly affected only by non-vegetarian diets; however the time to reach maximum serum concentration (Tmax) was prolonged and the maximum serum concentration (Cmax was decreased by all types of meals. The non-vegetarian diets affected the rate of absorption of loracarbef more than the vegetarian diets. The lowest decrease in Cmax was produced by the high-fat vegetarian diet, while the maximum was produced by the low-fat non-vegetarian diet. The results of this study indicate that while the rate of loracarbef absorption is significantly decreased by all diets, the extent of absorption is only reduced significantly by the non-vegetarian diets. The rate of elimination (k(el)) was not found to be significantly decreased by any of the diets. As compared to the high-fat non-vegetarian diet, the time beyond minimum inhibitory concentration (MIC90) concentration was significantly increased by the high-fat vegetarian diet. The implications of these findings for the large Indian vegetarian population are considerable.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18348469     DOI: 10.1007/BF03191005

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  17 in total

Review 1.  Food-drug interactions.

Authors:  Lars E Schmidt; Kim Dalhoff
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Evaluation of effect of food ingestion on bioavailability of cephalexin by moment analysis.

Authors:  J Haginaka; K Yamaoka; T Nakagawa; Y Nishimura; T Uno
Journal:  Chem Pharm Bull (Tokyo)       Date:  1979-12       Impact factor: 1.645

3.  Comparison of the effects of food on the pharmacokinetics of cefprozil and cefaclor.

Authors:  R H Barbhaiya; U A Shukla; C R Gleason; W C Shyu; K A Pittman
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

4.  A human pharmacology study of cefaclor.

Authors:  A Glynne; R A Goulbourn; R Ryden
Journal:  J Antimicrob Chemother       Date:  1978-07       Impact factor: 5.790

5.  Comparative pharmacokinetics of cephalexin, cefaclor, cefadroxil, and CGP 9000.

Authors:  H Lode; R Stahlmann; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1979-07       Impact factor: 5.191

Review 6.  The safety profile of loracarbef: clinical trials in respiratory, skin, and urinary tract infections.

Authors:  D G Therasse
Journal:  Am J Med       Date:  1992-06-22       Impact factor: 4.965

Review 7.  Effects of food on clinical pharmacokinetics.

Authors:  B N Singh
Journal:  Clin Pharmacokinet       Date:  1999-09       Impact factor: 6.447

Review 8.  Loracarbef. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  R N Brogden; D McTavish
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

9.  The absolute bioavailability of oral cefuroxime axetil in male and female volunteers after fasting and after food.

Authors:  P E Williams; S M Harding
Journal:  J Antimicrob Chemother       Date:  1984-02       Impact factor: 5.790

10.  Pharmacokinetics of loracarbef and interaction with acetylcysteine.

Authors:  S Roller; H Lode; I Stelzer; K M Deppermann; M Boeckh; P Koeppe
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-09       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.